| IPO Company Profile © ipodata.com |
| Message Board | SEC Filings | Peer IPO Companies |
| Neosurg Technologies, Inc. |
| 17300 El Camino Real, Suite 110, Houston, TX 77058 * (281) 461-6211 |
| Business Description | The company is a designer and manufacturer of surgical devices known as trocars that are used in all laparoscopic surgical procedures. |
|
Filing Information Not yet | |||
| To Trade As | - - (AMEX) | Industry | Manufacturing (SIC 3841) |
| Type of Stock Offered | Common Shares | Filing Date | 2/28/00 |
| Domestic Shares Filed | 2,400,000 | Filing Price | $6.75 |
| Foreign Shares Filed | 0 | Offering Amount | $16,200,000 |
| Company Shares | 2,400,000 | Est. Expenses | - - |
| Selling Shrhldrs Shares | 0 | Post-IPO Shares | 15,648,524 |
| Primary Underwriting Group | ||
| Underwriter Name | Participation | Underwriter Phone |
| Oxford Financial Group | Lead Manager |
| Income Statement and Cash Flow Summary | |||||||
| Prior Audited Income |
Latest Unaudited Income | ||||||
| Full Year Audited Figures | 9 Months Ending | ||||||
| Figures in U.S. millions except per share data | 12/31/98 | 12/31/99 | 9/30/99 | 9/30/00 | |||
| Revenues | - | - | - | 0.000 | 0.000 | 0.000 | 0.009 |
| Income from Oper. | - | - | - | -0.482 | -0.540 | -0.351 | -0.548 |
| Net Income | - | - | - | -0.447 | -0.498 | -0.311 | -0.548 |
| E.P.S | - | - | - | -0.040 | -0.040 | -0.030 | -0.040 |
| Revenue Growth (%) | - | - | - | - | - | ||
| Net Income Growth (%) | - | - | - | - | - | ||
| Oper. Profit Margin (%) | - | - | - | - | - | - | - |
| Net Profit Margin (%) | - | - | - | - | - | - | - |
| Cash Flow - Oper. | -0.62 | -0.36 | -0.47 | ||||
| Cash Flow - Inv. | -0.02 | -0.03 | -0.02 | ||||
| Cash Flow - Fin. | 0.27 | - | 0.47 | ||||
| Balance Sheet Summary and Financial Ratios | |||||
| Balance sheet as of: 9/30/00 | Financial Ratios | ||||
| Total Assets | 0.35 | Current Assets | 0.28 | Current Ratio | 0.54 |
| Total Liab. | 0.53 | Current Liab. | 0.53 | Debt Ratio | 149.63% |
| Total Equity | -0.18 | Working Cap. | -0.24 | Debt to Equity Ratio | - |
| Cash | 0.14 | Return on Assets | - | ||
| Use Of Proceeds |
The proceeds from the proposed offering will be used for intellectual property/property line acquisition, bridge loan payment, product development, marketing and advertising, additional personnel, insurance, inventory and equipment, working capital and general corporate purposes. |
| Legal Counsel Registrar Auditor | |
| Issuer's Law Firm | Cokinos, Bosien & Young |
| Registrar/Transfer Agent | Continental Stock Transfer & Trust Co |
| Auditor | Hein & Associates |
| Send us feedback if you would like to request that we hyperlink a firm on this page | |